Format

Send to

Choose Destination
Pharmacogenomics J. 2016 Aug;16(4):357-65. doi: 10.1038/tpj.2015.61. Epub 2015 Aug 18.

Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.

Xu Q1, Wu X1, Li M1, Huang H2,3, Minica C4, Yi Z5, Wang G6, Shen L1, Xing Q7, Shi Y1, He L1,7,8, Qin S1,2,3,8.

Author information

1
Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.
2
Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
3
Broad Institute of Harvard and MIT, Cambridge, MA, USA.
4
Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
5
Shanghai Institute of Mental Health, Shanghai, China.
6
Nanjing Medical University Affiliated Wuxi Mental Health Center, Wuxi, China.
7
Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
8
Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.

Abstract

Schizophrenia is a widespread mental disease with a prevalence of about 1% in the world population. Continuous long-term treatment is required to maintain social functioning and prevent symptom relapse of schizophrenia patients. However, there are considerable individual differences in response to the antipsychotic drugs. There is a pressing need to identify more drug-response-related markers. But most pharmacogenomics of schizophrenia have typically focused on a few candidate genes in small sample size. In this study, 995 subjects were selected for discovering the drug-response-related markers. A total of 77 single-nucleotide polymorphisms of 25 genes have been investigated for four commonly used antipsychotic drugs in China: risperidone, clozapine, quetiapine, and chlorpromazine. Significant associations with treatment response for several genes, such as CYP2D6, CYP2C19, COMT, ABCB1, DRD3 and HTR2C have been verified in our study. Also, we found several new candidate genes (TNIK, RELN, NOTCH4 and SLC6A2) and combinations (haplotype rs1544325-rs5993883-rs6269-rs4818 in COMT) that are associated with treatment response to the four drugs. Also, multivariate interactions analysis demonstrated the combination of rs6269 in COMT and rs3813929 in HTR2C may work as a predictor to improve the clinical antipsychotic response. So our study is of great significance to improve current knowledge on the pharmacogenomics of schizophrenia, thus promoting the implementation of personalized medicine in schizophrenia.The Pharmacogenomics Journal advance online publication, 18 August 2015; doi:10.1038/tpj.2015.61.

PMID:
26282453
DOI:
10.1038/tpj.2015.61
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center